You are here: Industry Insights > Shire

News List

Shire submits IND application for SHP654 to treat haemophilia A pharmaceutical-technology
July 11, 2017
Irish-headquartered Shire has submitted an investigational new drug (IND) application to the US Food and Drug Administration (FDA) for SHP654, also designated as BAX 888, an investigational factor VIII (FVIII) gene therapy to treat haemophilia A.
Shire on Haemophilia: How to treat a bleeding disorder europeanpharmaceuticalreview
June 27, 2017
We caught up with Naghmana Bajwa, MD, Global Medical Affairs Haematology Lead at Shire to find out the latest in haemophilia disease research…
Shire secures US nod for once-daily ADHD drug pharmatimes
June 23, 2017
Shire has finally bagged approval in the US for its long-acting attention deficit hyperactivity disorder drug (ADHD) Mydayis.
Shire long-acting ADHD drug finally approved pharmaphorum
June 22, 2017
Shire’s long-acting attention deficit drug has been approved in the US after languishing in regulatory purgatory for more than a decade.
Kamada Receives Additional Shire Milestone contractpharma
June 13, 2017
Achieves sales milestone in GLASSIA supply and distribution agreement
Shire and Parion Sciences Enter into Collaborative Agreement to Advance P-321 americanpharmaceuticalreview
May 02, 2017
Shire and Parion Sciences announced they have entered into an agreement granting Shire exclusive worldwide rights to develop and commercialize P-321.
Shire Licenses Parion's Dry Eye Drug contractpharma
May 02, 2017
Gains exclusive rights to develop and commercialize P-321, an investigational epithelial sodium channel (ENaC) inhibitor
Shire granted EU conditional marketing authorisation for Natpar for the treatment of chronic hypopar cphi-online
April 27, 2017
Natpar is the first and only licensed recombinant human parathyroid hormone therapy for chronic hypoparathyroidism.
PatientsLikeMe and Shire Pharmaceuticals collaborate to study rare genetic diseases worldpharmanews
April 12, 2017
PatientsLikeMe and Shire plc (LSE: SHP, NASDAQ: SHPG) have announced a new collaboration that will support the development of a patient-centered, real world health learning system that expands understanding of patient health and disease.
NICE does not recommend Shire’s pancreatic cancer drug europeanpharmaceuticalreview
April 05, 2017
The National Institute or Health and Care Excellence (NICE) has published final guidance that does not recommend pegylated liposomal irinotecan (Onivyde, Shire).

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page